At first glance, the curious thing about the failure of Sylentis S.A.U.’s tivanisiran in a Phase III trial in dry-eye disease associated with Sjögren’s syndrome is that it follows a late-stage hit in standard dry eye disease. Look closer, however, and there is little evidence of the drug’s efficacy to be gleaned from either trial.
Key Takeaways
- Sylentis’s RNAi drug tivanisiran has failed in Phase III in dry-eye disease associated with Sjögren’s syndrome
The FYDES trial, tivanisiran’s success in which was disclosed in December, was simply a safety study: no efficacy endpoints were...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?